Literature DB >> 28428258

Deletion of inositol-requiring enzyme-1α in podocytes disrupts glomerular capillary integrity and autophagy.

Daniel Robert Kaufman1, Joan Papillon2, Louise Larose2, Takao Iwawaki3, Andrey V Cybulsky4,2.   

Abstract

Inositol-requiring enzyme-1α (IRE1α) is an endoplasmic reticulum (ER)-transmembrane endoribonuclease kinase that plays an essential function in extraembryonic tissues during normal development and is activated during ER stress. To address the functional role of IRE1α in glomerular podocytes, we produced podocyte-specific IRE1α-deletion mice. In male mice, deletion of IRE1α in podocytes resulted in albuminuria beginning at 5 mo of age and worsening with time. Electron microscopy revealed focal podocyte foot-process effacement in 9-mo-old male IRE1α-deletion mice, as well as microvillous transformation of podocyte plasma membranes. Compared with control, glomerular cross-sectional and capillary lumenal areas were greater in deletion mice, and there was relative podocyte depletion. Levels of microtubule-associated protein 1A/1B-light chain 3 (LC3)-II expression and c-Jun N-terminal kinase-1 phosphorylation were decreased in IRE1α-deletion glomeruli, in keeping with reduced autophagy. Deletion of IRE1α exacerbated glomerular injury in anti-glomerular basement membrane nephritis. In cell culture, IRE1α dominant-negative mutants reduced the physiological (basal) accumulation of LC3B-II and the size of autophagic vacuoles but did not affect ER-associated degradation. Thus IRE1α is essential for maintaining podocyte and glomerular integrity as mice age and in glomerulonephritis. The mechanism is related, at least in part, to the maintenance of autophagy in podocytes.
© 2017 Kaufman et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28428258      PMCID: PMC5469607          DOI: 10.1091/mbc.E16-12-0828

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


INTRODUCTION

The endoplasmic reticulum (ER) is an organelle with many critical roles, including calcium homeostasis and the folding and maturation of proteins that are trafficked along the secretory pathway (Araki and Nagata, 2011). Inositol-requiring enzyme 1α (IRE1α) is an ER-transmembrane protein and a sensor of misfolded protein accumulation in the ER, which leads to ER stress (Hetz and Glimcher, 2009; Araki and Nagata, 2011; Hetz, 2012). By splicing X-box binding protein-1 (Xbp1) mRNA, IRE1α serves as a transcriptional inducer of the unfolded protein response (UPR). The importance of IRE1α in the maintenance of normal mammalian physiology and embryogenesis has been demonstrated in vivo, although its physiological mechanism of action is poorly understood (Iwawaki ). Indeed, studies of the physiological role of IRE1α in adult mice are limited in number due to embryonic lethality of global IRE1α deletion (Iwawaki ). The IRE1-mediated UPR branch is the most evolutionarily conserved branch in eukaryotes. In yeast, IRE1 is the only ER sensor. In mammals, besides IRE1, two other proteins modulate distinct branches of the UPR, including activating transcription factor 6 (ATF6) and protein kinase R–like endoplasmic reticulum kinase (PERK). Mammalian IRE1 splices Xbp1 mRNA, which is homologous to yeast Hac1p. There are two isoforms of IRE1 in mammals—IRE1α, which is expressed ubiquitously, and IRE1β, which is expressed in gut epithelium (Hetz and Glimcher, 2009; Hetz, 2012). The UPR acts to reduce the amount of misfolded protein and facilitates elimination of terminally misfolded glycoproteins. This involves up-regulation of genes encoding pro-folding ER-resident chaperones and components of ER-associated degradation (ERAD; Vembar and Brodsky, 2008). ERAD is a process that selects and retrotranslocates terminally misfolded proteins from the ER, trafficking them to the cytoplasm for degradation by the 26S proteasome (Vembar and Brodsky, 2008). IRE1α has been linked to the up-regulation of UPR and ERAD genes (Hetz and Glimcher, 2009; Hetz, 2012), but direct associations between IRE1α and substrates undergoing ERAD have not been confirmed. The general steps in ERAD have been well characterized through insights gained from yeast and mammalian studies (Vembar and Brodsky, 2008; Sun ). Even under basal conditions, ER protein glycosylation, folding, and maturation is believed to be an imperfect process, and normally, a fraction of certain wild-type (WT) proteins is constitutively degraded via ERAD because of minor folding errors or ill-timed exposure of hydrophobic patches. Such proteins include T-cell coreceptor components (e.g., CD3δ) and the cystic fibrosis transmembrane regulator (Bonifacino ; Varga ). Thus constitutive, physiological ERAD is potentially required to prevent ER stress. There is emerging evidence to support the view that autophagy is linked with the UPR and is another major mechanism to clear misfolded proteins from the secretory pathway, thereby alleviating ER stress (Cybulsky, 2013). IRE1α has been linked to autophagic degradation of misfolded proteins in studies of ER stress in vitro but not in vivo (Ogata ; Oh and Lim, 2009; Lee ). Autophagy is a term used to describe three interrelated pathways of protein and organellar degradation: macroautophagy (commonly referred to as autophagy), chaperone-mediated autophagy, and microautophagy (Cuervo, 2004; Huber ). Autophagy begins with the formation of a double membrane (phagophore) that engulfs a portion of the cytoplasm. Eventually, the membrane encloses to form a vesicle (autophagosome), which then fuses with a lysosome, leading to the degradation of vesicular content by lysosomal hydrolases. Among signaling pathways known to regulate the formation of autophagosomes, inhibition of the mammalian target of rapamycin (mTOR) pathway resulting from growth factor deprivation is well established (Jung ; Yang and Klionsky, 2010). Within this context, activation of the c-Jun amino-terminal kinase-1 (JNK1) and the death-associated protein kinase also contributes to this process by targeting beclin-1, a protein playing a critical role in the regulation of autophagy (Yang and Klionsky, 2010). Formation of autophagosomes involves conjugation of phosphatidylethanolamine to free microtubule-associated protein 1A/1B-light chain 3 (LC3), or LC3-I. Lipidated LC3 (LC3-II) redistributes from the cytosol to autophagic vacuole membranes and is therefore commonly used as a marker of autophagy. In many cells, basal autophagosome turnover and the basal quantity of autophagosomes are low. Basal/constitutive autophagy is involved in degradation of long-lived proteins and organelle turnover. IRE1α forms a stable complex with tumor necrosis factor-α receptor–associated factor 2 (TRAF2; an E3 ubiquitin ligase and adaptor protein) and apoptosis signal–regulated kinase 1 (ASK1; Hetz and Glimcher, 2009; Hetz, 2012). The IRE1α–TRAF2 interaction has been localized to the IRE1α RNase domain (Kaneko ). The IRE1α–TRAF2 complex has also been demonstrated to act as a positive regulator of autophagy. Double IRE1α and IRE1β–knockout (KO) mouse embryonic fibroblasts were deficient in ER stress–mediated autophagosome formation, as were WT fibroblasts expressing a dominant-negative TRAF2 mutant (Ogata ). IRE1α knockdown in WI38 cells prevented dihydrocapsaicin-mediated autophagosome formation, and a JNK1 inhibitor prevented autophagosome formation in the presence of dihydrocapsaicin, thapsigargin, or MG132 (Oh and Lim, 2009). Knockdown of TRAF2 decreased autophagic flux induced by the autophagic enhancer tumor necrosis factor superfamily member 10 (He ). TRAF2 was reported to colocalize with mitochondria in autophagosomes and was required for the induction of mitophagy (Yang ). Finally, IRE1α was required for lysosomal (and proteasomal) degradation of a misfolded rhodopsin mutant (Chiang ). Besides autophagy, IRE1α may influence proteasomal activity via ASK1; in particular, ASK1 may negatively regulate the 26S proteasome by inactivating Rpt5, an AAA ATPase of the 19S proteasome (Um ). Given that ERAD requires 26S proteasomal activity, these studies suggest an inhibitory role of IRE1α in ERAD. In recent years, strains of conditional IRE1α-deletion mice have been generated. Mice with IRE1α deletion in extraplacental tissues exhibited mild hypoinsulinemia, hyperglycemia, and a low-weight trend (Iwawaki ). In T-cell–specific IRE1α-deletion mice, CD4 T-cells showed reduced interleukin-4 expression due to reduced interleukin-4 mRNA stability (Kemp ). Deletion of IRE1α in bone marrow cells increased bone mass as the result of defective osteoclastic bone resorption (Tohmonda ). IRE1α deletion in pro-opiomelanocortin neurons in the hypothalamus decreased fat mass by increasing energy expenditure (Xiao ). Conditional deletion of Xbp1 has been performed in various mouse strains, and this has resulted in hyperactivation of IRE1α activity, including regulated IRE1α-dependent decay of cytosolic mRNAs (Hur ). Moreover, the phenotypes of Xbp1 and IRE1α mice with conditional deletion in the same tissue are distinct (Hur ), which suggests that IRE1α may perform physiological activities in a manner that does not depend on Xbp1 splicing. Glomerular visceral epithelial cells, also known as podocytes, are highly differentiated cells in the kidney glomerulus that play an important role in the regulation of glomerular permselectivity, that is, filtration of plasma but restriction of proteins (Tryggvason and Wartiovaara, 2001; Chiang and Inagi, 2010; Greka and Mundel, 2012; Welsh and Saleem, 2012; Brinkkoetter ). Podocytes reveal a complex morphology characterized by cell bodies and projecting foot processes that adhere to the glomerular basement membrane (GBM). Filtration slit diaphragms are localized between foot processes and help maintain the permselectivity of the glomerular filter. This intricate shape of podocytes is supported by the actin cytoskeleton, which allows podocytes to alter their shape dynamically (Tryggvason and Wartiovaara, 2001; Chiang and Inagi, 2010; Greka and Mundel, 2012; Welsh and Saleem, 2012; Brinkkoetter ). Podocytes and glomerular endothelial cells produce the key structural components of the GBM, including collagens and laminins. Various glomerular diseases are associated with disruption of the actin cytoskeleton or surface charge of podocytes, resulting in effacement of foot processes, detachment from the GBM, and development of albuminuria and glomerulosclerosis, as well as impairment of glomerular function (Pippin ; Chiang and Inagi, 2010). Autophagy and ER stress have been implicated in podocyte pathophysiology (Hartleben ; Huber ; Cybulsky, 2013). The beclin-1–mediated pathway that regulates autophagy may be particularly important in maintaining podocyte homeostasis. Indeed, deficient JNK1 phosphorylation accompanied by deficient autophagy and elevated ER stress were reported in podocyte-specific Atg5 KO mice (Kawakami ). Basal auto­phagy was suppressed in podocytes exposed to high glucose concentrations; furthermore, beclin-1 knockdown suppressed basal autophagy in podocytes and disrupted the podocyte filtration barrier integrity, as measured in vitro by albumin leakage (Fang ). Deficient autophagy in podocytes was shown to worsen proteinuria and podocyte loss in a murine model of diabetic nephropathy (Tagawa ). Autophagy was also implicated in the podocyte ER stress response in vitro (Cheng ). In the present study, we generated mice with podocyte-specific deletion of the IRE1α gene to characterize its role in podocyte pathophysiology. We show that mice with podocyte-specific deletion of IRE1α developed severe podocyte injury and albuminuria as they aged. In addition, loss of IRE1α impaired autophagy in podocytes.

RESULTS

IRE1α exons 20 and 21 are deleted in podocin-Cre IRE1α flox/flox mice

In the present study, mice with loxP sites surrounding exons 20 and 21 of IRE1α gene were crossed with mice expressing a Cre recombinase under the control of the podocyte-specific podocin promoter. This breeding strategy is expected to delete exons 20 and 21 specifically in podocytes, resulting in the expression of an RNase-domain truncated (ΔR) IRE1α mutant (Iwawaki ). In glomeruli, PCR primers were designed to amplify a 1025–base pair predeletion product of the IRE1α loxP allele and a 189–base pair postdeletion product that is expected to appear after Cre-dependent excision of IRE1α-loxP exons 20 and 21 (Supplemental Figure S1A). Mice were initially genotyped by amplifying the IRE1α and podocin-Cre genes in tail DNA. We confirmed the presence of expected IRE1α and podocin-Cre bands in IRE1αflox/flox;Cre mice (loxP-homozygous deletion) and IRE1αflox/+;Cre mice (loxP-heterozygous deletion; Supplemental Figure S1B). To confirm a functional deletion in podocytes, we conducted PCR amplification using glomerular genomic DNA from IRE1αflox/+;Cre and IRE1αflox/flox;Cre (LoxP-heterozygous and LoxP-homozygous deletion) mice. Both loxP-heterozygous and -homozygous deletion glomeruli expressed a prominent 189–base pair deletion product, which was much more intense in homozygous mice (Supplemental Figure S1C). The unspliced loxP allele (1025 base pairs) was also amplified in these mice because glomeruli contain endothelial cells, mesangial cells, and parietal epithelial cells in addition to podocytes, and Cre recombinase is not active in these nonpodocyte cells. The WT IRE1α allele, which is slightly larger than the native loxP allele (1294 base pairs), was amplified in heterozygous mice (Supplemental Figure S1C).

Male mice with podocyte-specific deletion of IRE1α develop age-dependent podocyte injury

To determine whether podocyte-specific IRE1α gene deletion perturbs podocyte health, we generated podocin-Cre IRE1αflox/flox male and female mice (IRE1αflox/flox;Cre). The podocin-Cre allele was absent in littermate controls (IRE1αflox/flox:+; WT). Monthly urine albumin/creatinine ratio was analyzed separately in male (M) and female (F) WT (+) and deletion (Cre) mice because basal albuminuria is typically greater in male mice. We did not observe significant differences in either gender between 1 and 4 mo of age (Figure 1, A and B). However, at 5 mo of age, M Cre mice developed persistent and worsening albuminuria compared with M + mice (Figure 1A). In contrast, the albumin/creatinine ratio remained relatively low in female mice at all ages, except for an increase in elderly female mice (11–13 mo), which was independent of genotype (Figure 1B). Serum creatinine in 9-mo-old male mice was not significantly different between M Cre (8.36 ± 0.35 μM; N = 5) and M + mice (9.14 ± 0.43 μM; N = 5), implying that IRE1α deletion did not affect renal function.
FIGURE 1:

Podocyte IRE1α-deletion male mice develop albuminuria with aging. Male (A) and female (B) F3 littermates were monitored for albuminuria monthly. Podocyte IRE1α deletion in male mice (IRE1αflox/flox;Cre; M Cre) caused persistent and worsening albuminuria beginning at 5 mo of age as compared with control (IRE1αflox/flox;+; M +). Male mice: p = 4.72 × 10–4 (M Cre vs. M +; genotype); p = 2.20 × 10–6 (age); p = 0.033 (genotype × age interaction). There were no significant differences in albuminuria between female Cre (F Cre) and control (F +) mice. Number of urine samples (N) is indicated under each column.

Podocyte IRE1α-deletion male mice develop albuminuria with aging. Male (A) and female (B) F3 littermates were monitored for albuminuria monthly. Podocyte IRE1α deletion in male mice (IRE1αflox/flox;Cre; M Cre) caused persistent and worsening albuminuria beginning at 5 mo of age as compared with control (IRE1αflox/flox;+; M +). Male mice: p = 4.72 × 10–4 (M Cre vs. M +; genotype); p = 2.20 × 10–6 (age); p = 0.033 (genotype × age interaction). There were no significant differences in albuminuria between female Cre (F Cre) and control (F +) mice. Number of urine samples (N) is indicated under each column.

Male mice with podocyte-specific deletion of IRE1α display enlarged glomeruli, capillary distension, and abnormal collagen deposition

Glomerular morphology and ultrastructure, as well as expression of podocyte markers, were investigated in 9-mo-old M + and M Cre mice from the same cohort used to determine age-dependent albuminuria. Based on light microscopy (periodic acid Schiff [PAS]–stained kidney sections; Figure 2A) and low-power electron micrographs (Figure 3A), M Cre glomeruli appeared to be enlarged, with particularly large glomerular capillaries, compared with M + mice. This visual impression was confirmed using an imaging-based approach demonstrating that the mean cross-sectional area of M Cre glomeruli was greater than with M + (Figure 2, A and C). This enlargement can be explained by a near-exact proportional rise in the glomerular cross-sectional area occupied by glomerular capillary lumens (Figure 2, A and D). In contrast, prealbuminuric 4- to 5-mo-old M Cre mice showed no evidence of glomerular volume expansion compared with M + mice, using PAS-stained glomeruli (unpublished data). In 9-mo-old male mice, we also used the Jones silver stain to accentuate the collagenous structures in the GBM and mesangial matrix. Using an imaging-based approach, we confirmed that 9-mo-old M Cre glomeruli contain excessive collagen in the capillary walls and mesangium compared with M + mice (Figure 2, B and E).
FIGURE 2:

Podocyte IRE1α deletion causes glomerular volume expansion and distended capillary loops, as well as collagen deposition, at 9 mo of age. (A) PAS stain. IRE1αflox/flox;Cre (M Cre) mice have enlarged glomeruli, as well as enlarged glomerular capillary lumens, compared with control (IRE1αflox/flox;+; M +). (B) There is increased capillary wall and mesangial collagen deposition in M Cre mice (Jones’ silver stain). (C) PAS-stained glomerular area is increased in M Cre mice (*p = 3.1 × 10−5). Mean of 48 M + glomeruli from three mice and 56 M Cre glomeruli from three mice. (D) Percentage of a given PAS-stained glomerulus that is occupied by capillary lumen is expanded in M Cre mice (*p = 0.0066). Average of 48 M + glomeruli from three mice, and 55 M Cre glomeruli from three mice. (E) Silver-stained glomeruli of M Cre mice have a higher fraction of glomerular tissue occupied by collagen than M + mice (*p = 1.45 × 10−5). Because the expanded capillary lumens in M Cre mice could confound this analysis, the capillary luminal area was subtracted from total glomerular cross-sectional area, so that the area of stained tissue could then be normalized to the total cross-sectional area of glomerular tissue. Imaging and quantification included 75 M + glomeruli from three mice and 74 M Cre glomeruli from three mice.

FIGURE 3:

Podocyte IRE1α deletion results in ultrastructural changes in podocytes. (A–C) Representative electron micrographs from 9-mo-old IRE1αflox/flox;+ (M +) and IRE1αflox/flox;Cre (M Cre) mice. (A) At low power, glomerular capillaries appear markedly dilated in M Cre mice (CL, capillary lumen). (B) Glomerular capillary walls from 2 M + and 2 M Cre mice reveal widened and effaced podocyte foot processes in the M Cre mice (Ψ). (C) M + and M Cre podocyte (P) cell bodies. M + mice displayed evidence of active autophagy, that is, autophagosomes or autolysosomes (AL). Lysosomes (L) were present in M Cre and M + mice. M Cre podocytes show focal foot process widening (Ψ), occludens junctions (*), and microvillous transformation of the plasma membranes (arrows). (D) Quantification of M Cre focal podocyte foot process widening (*p = 3.9 × 10−7). Foot processes were measured in 63 lengths of GBM from three M Cre mice and 20 lengths of GBM from two M + mice.

Podocyte IRE1α deletion causes glomerular volume expansion and distended capillary loops, as well as collagen deposition, at 9 mo of age. (A) PAS stain. IRE1αflox/flox;Cre (M Cre) mice have enlarged glomeruli, as well as enlarged glomerular capillary lumens, compared with control (IRE1αflox/flox;+; M +). (B) There is increased capillary wall and mesangial collagen deposition in M Cre mice (Jones’ silver stain). (C) PAS-stained glomerular area is increased in M Cre mice (*p = 3.1 × 10−5). Mean of 48 M + glomeruli from three mice and 56 M Cre glomeruli from three mice. (D) Percentage of a given PAS-stained glomerulus that is occupied by capillary lumen is expanded in M Cre mice (*p = 0.0066). Average of 48 M + glomeruli from three mice, and 55 M Cre glomeruli from three mice. (E) Silver-stained glomeruli of M Cre mice have a higher fraction of glomerular tissue occupied by collagen than M + mice (*p = 1.45 × 10−5). Because the expanded capillary lumens in M Cre mice could confound this analysis, the capillary luminal area was subtracted from total glomerular cross-sectional area, so that the area of stained tissue could then be normalized to the total cross-sectional area of glomerular tissue. Imaging and quantification included 75 M + glomeruli from three mice and 74 M Cre glomeruli from three mice. Podocyte IRE1α deletion results in ultrastructural changes in podocytes. (A–C) Representative electron micrographs from 9-mo-old IRE1αflox/flox;+ (M +) and IRE1αflox/flox;Cre (M Cre) mice. (A) At low power, glomerular capillaries appear markedly dilated in M Cre mice (CL, capillary lumen). (B) Glomerular capillary walls from 2 M + and 2 M Cre mice reveal widened and effaced podocyte foot processes in the M Cre mice (Ψ). (C) M + and M Cre podocyte (P) cell bodies. M + mice displayed evidence of active autophagy, that is, autophagosomes or autolysosomes (AL). Lysosomes (L) were present in M Cre and M + mice. M Cre podocytes show focal foot process widening (Ψ), occludens junctions (*), and microvillous transformation of the plasma membranes (arrows). (D) Quantification of M Cre focal podocyte foot process widening (*p = 3.9 × 10−7). Foot processes were measured in 63 lengths of GBM from three M Cre mice and 20 lengths of GBM from two M + mice.

M Cre podocytes exhibit focal foot-process widening, microvillous transformation, and ectopic formation of occludens junctions

Having identified histological abnormalities in M Cre mice, we further studied glomerular ultrastructure by electron microscopy. As noted earlier, in the 9-mo-old M Cre mice, there were clear examples of capillary dilation (Figure 3A), although we did not see any morphological changes in the structure of the GBM (Figure 3, A–C). Podocyte foot processes were focally effaced, with some regions appearing relatively normal and others being severely effaced (Figure 3, B and C). Quantification of the number of foot processes per unit of length along the GBM showed that there was a significant increase in the mean foot process width (giving fewer foot processes per unit length of GBM) in M Cre mice (Figure 3D). Further, in M Cre mice, we observed podocyte microvillous transformation, a hallmark of podocyte injury, which was not apparent in M + mice (Figure 3C). Occasionally, occludens junctions had formed between some M Cre podocyte foot processes, replacing slit diaphragms, in keeping with dedifferentiation of podocytes. We noted early, mature, and late endosomes, as well as endolysosomal fusion, in both M + and M Cre podocytes (Figure 3C). Occasional phagophore engulfment, mature autophagosomes, and autolysosomes were observed in electron micrographs from M + podocytes, whereas normal or typical autophagosomes were absent in M Cre podocytes. Specifically, 11 normal autophagosomes (including a nascent phagophore and some autophagosomes fusing with lysosomes) were identified in 10 M + electron micrographs from two mice. Only five misshapen autophagosomes were identified in 20 M Cre electron micrographs from three mice, all of which contained unusual cargo or unusually shaped double membranes. We did not identify changes in the ultrastructure of podocyte organelles, including nuclei, mitochondria, rough ER, and the Golgi apparatus, between both mouse genotypes (Figure 3C).

IRE1α deletion leads to relative podocyte depletion

Next we investigated whether the albuminuria in 9-mo-old M Cre mice was associated with podocyte loss. We conducted immunofluorescence staining for Wilms tumor-1 (WT1; a protein expressed specifically in the nucleus of the podocyte) to monitor the average number of podocytes per glomerular cross section (Venkatareddy ). Although there were no significant differences in WT1-positive nuclei per glomerulus between 9-mo-old M Cre and M + mice, WT1 counts per unit glomerular area were significantly lower in the M Cre mice, indicating relative podocyte depletion (Figure 4, A, D, and E). To further support this finding, we used immunofluorescence microscopy to compare glomerular expression of synaptopodin and podocalyxin in mice from the same cohort (Figure 4, B and C). Synaptopodin is a podocyte-specific protein, and its depletion is viewed as a marker of podocyte injury, whereas podocalyxin, which is expressed in podocytes and glomerular endothelial cells, participates in a number of important functions in podocytes (Greka and Mundel, 2012). M Cre glomeruli, which were significantly enlarged (Figure 4, F and H, and as demonstrated in Figure 2), stained positively for both synaptopodin and podocalyxin (Figure 4, B and C). Synaptopodin fluorescence normalized per unit of glomerular cross-sectional area was significantly lower in M Cre mice (Figure 4G). Podocalyxin fluorescence per unit of glomerular area tended to be reduced in M Cre mice, but the difference did not reach statistical significance (Figure 4I), perhaps due to the glomerular endothelial component, which would not be expected to change.
FIGURE 4:

Podocyte IRE1α deletion result in a reduction of WT1 and synaptopodin. (A–C) Kidney sections from 9-mo-old mice were stained with antibodies to WT1 (A), synaptopodin (B), and podocalyxin (C). Staining with nonimmune IgG is also presented (negative controls). Scale bars, 50 μm. (D, E) The number of WT1-positive nuclei per glomerulus (determined by colocalization with Hoechst nuclear stain; not shown) was assessed by visual counting. WT1 counts per glomerulus were comparable, but when expressed per 1000 µm2 of glomerular area, WT1 counts were significantly lower in M Cre mice (*p = 4.6 × 10−5); 32 M + glomeruli from three mice and 48 M Cre glomeruli from three mice. (F) Synaptopodin-stained glomeruli were enlarged in M Cre mice (*p = 0.024). (G) Quantification of synaptopodin immunofluorescence per unit glomerular area showed that intensity was lower in M Cre mice (*p = 0.046). For F and G, 74 M + glomeruli from three mice and 69 M Cre glomeruli from three mice. (H) Podocalyxin-stained glomeruli were enlarged in M Cre mice (*p = 0.0013). (I) Podocalyxin fluorescence per glomerulus and fluorescence per unit glomerular area were comparable in both groups. For H and I, 58 M + glomeruli from three mice and 54 M Cre glomeruli from three mice.

Podocyte IRE1α deletion result in a reduction of WT1 and synaptopodin. (A–C) Kidney sections from 9-mo-old mice were stained with antibodies to WT1 (A), synaptopodin (B), and podocalyxin (C). Staining with nonimmune IgG is also presented (negative controls). Scale bars, 50 μm. (D, E) The number of WT1-positive nuclei per glomerulus (determined by colocalization with Hoechst nuclear stain; not shown) was assessed by visual counting. WT1 counts per glomerulus were comparable, but when expressed per 1000 µm2 of glomerular area, WT1 counts were significantly lower in M Cre mice (*p = 4.6 × 10−5); 32 M + glomeruli from three mice and 48 M Cre glomeruli from three mice. (F) Synaptopodin-stained glomeruli were enlarged in M Cre mice (*p = 0.024). (G) Quantification of synaptopodin immunofluorescence per unit glomerular area showed that intensity was lower in M Cre mice (*p = 0.046). For F and G, 74 M + glomeruli from three mice and 69 M Cre glomeruli from three mice. (H) Podocalyxin-stained glomeruli were enlarged in M Cre mice (*p = 0.0013). (I) Podocalyxin fluorescence per glomerulus and fluorescence per unit glomerular area were comparable in both groups. For H and I, 58 M + glomeruli from three mice and 54 M Cre glomeruli from three mice.

M Cre podocytes are deficient in autophagy

IRE1α is a mediator of the UPR and has also been linked to autophagy. To determine whether podocyte-specific deletion of IRE1α affects UPR and autophagy, we isolated glomeruli from prealbuminuric male mice (age 4–5 mo) and assessed UPR and autophagy markers by immunoblotting. M Cre mouse glomeruli exhibited elevated levels of the ER chaperones Grp78 and Grp94, suggesting activation of the ATF6 UPR pathway (Figure 5, A, C, and D). In contrast, phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) on Ser-51 and the levels of C/EBP homologous protein (CHOP) were quite variable among mice, but mean values were comparable between the M + and M Cre groups, suggesting that the PERK pathway was not activated in M Cre glomeruli (Supplemental Figure S2A). In addition, M Cre glomeruli displayed elevated global ubiquitination of proteins, consistent with accumulation of misfolded proteins (Figure 5, B and H). In M Cre glomeruli, there was evidence of deficient autophagy, as determined by a lower LC3B-II/I ratio (Figure 5, A and E), and a reduced absolute amount of LC3B-II, that is, LC3B-II normalized to actin (Figure 5F). Decreased LC3B-II/I ratio or amount of LC3B-II in the M Cre glomeruli compared with M + mice implies deficient autophagic vacuole flux. Finally, in contrast to older mice (see later discussion), we did not observe reduced glomerular JNK1 (46 kDa) phosphorylation in the prealbuminuric M Cre mice; perhaps changes in JNK1 phosphorylation were below detectability (Figure 5, A and G). Phosphorylation of JNK2 (54 kDa) was poorly detected in glomerular lysates (unpublished data).
FIGURE 5:

Podocyte IRE1α deletion induces ER stress and causes deficient autophagosome turnover in 4- to 5-mo-old prealbuminuric mice. (A, B) Glomerular lysates were immunoblotted with antibodies as indicated. Representative immunoblots of four IRE1αflox/flox;+ (M +) and four IRE1αflox/flox;Cre (M Cre) mice obtained from a cohort of prealbuminuric male mice. (C, D) Densitometric quantification. M Cre mice show elevated expression of Grp78 (*p = 0.033) and Grp94 (*p = 0.0017). No change in calnexin was noted (B). (B, H) M Cre mice display elevated global polyubiquitinated proteins (*p = 0.0015). (A, E, F) M Cre mice show decreased LC3B-II, normalized either to LC3B-I (*p = 0.023) or actin (*p = 0.043; five to seven mice per group); M Cre mice show a reduced LC3B-II/I ratio (*p = 0.002). There were no differences in total LC3B-I or phospho-JNK1 (pJNK1) between groups (F, G).

Podocyte IRE1α deletion induces ER stress and causes deficient autophagosome turnover in 4- to 5-mo-old prealbuminuric mice. (A, B) Glomerular lysates were immunoblotted with antibodies as indicated. Representative immunoblots of four IRE1αflox/flox;+ (M +) and four IRE1αflox/flox;Cre (M Cre) mice obtained from a cohort of prealbuminuric male mice. (C, D) Densitometric quantification. M Cre mice show elevated expression of Grp78 (*p = 0.033) and Grp94 (*p = 0.0017). No change in calnexin was noted (B). (B, H) M Cre mice display elevated global polyubiquitinated proteins (*p = 0.0015). (A, E, F) M Cre mice show decreased LC3B-II, normalized either to LC3B-I (*p = 0.023) or actin (*p = 0.043; five to seven mice per group); M Cre mice show a reduced LC3B-II/I ratio (*p = 0.002). There were no differences in total LC3B-I or phospho-JNK1 (pJNK1) between groups (F, G). The foregoing parameters were also studied in glomerular lysates from albuminuric 9-mo-old M Cre and M + mice (Figure 6A). The amount of autophagosomes was significantly lower in M Cre glomeruli, as determined by both reduced LC3B-II/I ratio and reduced LC3B-II (LC3B-II/actin ratio; Figure 6, A–C). Moreover, JNK1 phosphorylation was significantly lower in M Cre glomeruli, consistent with deficient beclin-1–associated autophagic induction (Figure 6, A and D). Grp78 and Grp94, as well as phospho-eIF2α and CHOP, did not differ between M Cre and M + mice, indicating that neither ER stress nor the UPR was substantially induced in 9-mo-old M Cre glomeruli in spite of impaired autophagy (Figure 6, A, E, and F, and Supplemental Figure S2B). We also assessed polyubiquitinated proteins in glomerular lysates from both mouse genotypes, but in contrast to our findings in prealbuminuric male mice, there was no difference between M Cre and M + mice (unpublished data). Expression levels of autophagy mediators, including beclin-1, Atg5, and Atg3, were not significantly different between 9-mo-old M Cre and M + mice, implying that autophagic activity was regulated posttranslationally and not transcriptionally in M Cre mouse glomeruli (Supplemental Figure S2B).
FIGURE 6:

Mice with podocyte IRE1α deletion are deficient in autophagy but do not show ER stress at 9 mo of age. (A) Glomerular lysates were immunoblotted with antibodies as indicated. Representative immunoblots of 5 IRE1αflox/flox;+ (M +) and 5 IRE1αflox/flox;Cre (M Cre) mice. (B–D) Densitometric quantification. M Cre mice show decreased LC3B-II, normalized either to LC3B-I (*p = 0.013) or actin (*p < 0.0001), and decreased JNK1 phosphorylation (*p = 0.048). (E–I) No significant differences between M Cre and M + mice were observed in Grp78, Grp94, podocalyxin, nephrin maturation (upper/lower band), or mature nephrin expression (upper band).

Mice with podocyte IRE1α deletion are deficient in autophagy but do not show ER stress at 9 mo of age. (A) Glomerular lysates were immunoblotted with antibodies as indicated. Representative immunoblots of 5 IRE1αflox/flox;+ (M +) and 5 IRE1αflox/flox;Cre (M Cre) mice. (B–D) Densitometric quantification. M Cre mice show decreased LC3B-II, normalized either to LC3B-I (*p = 0.013) or actin (*p < 0.0001), and decreased JNK1 phosphorylation (*p = 0.048). (E–I) No significant differences between M Cre and M + mice were observed in Grp78, Grp94, podocalyxin, nephrin maturation (upper/lower band), or mature nephrin expression (upper band). Nephrin is an important podocyte-resident protein that undergoes posttranslational modification in the ER. It is expressed as a fully glycosylated mature form (∼180 kDa), as well as an immature, ER-luminal form (∼170 kDa; Figure 6A). There were no significant differences between M + and M Cre mice in the ratio of mature to immature nephrin (Figure 6H) or total amount of mature nephrin, that is, nephrin normalized to actin (Figure 6I). For comparison, expression of podocalyxin (expressed in podocytes and glomerular endothelial cells) was also not different between M Cre and M + mice (Figure 6, A and G).

M Cre mice are more susceptible to injury in acute anti-GBM nephritis

Although deletion of IRE1α did not lead to development of overt albuminuria in mice up to 4–5 mo of age, we hypothesized that deletion of IRE1α in these mice would nonetheless predispose them to podocyte injury. To test this hypothesis, we induced acute anti-GBM nephritis in prealbuminuric, 5-mo-old M Cre and M + mice, using a single intravenous injection of anti-GBM antibody. We selected a low dose of antibody in order to allow the unmasking of any potential contribution of IRE1α to podocyte integrity. After 24 h, anti-GBM antibody tended to induce a modest increase in the albumin/creatinine ratio in the M + control mice. In contrast, M Cre mice showed a significantly greater albumin/creatinine ratio, compared with both anti-GBM injected M + mice and control M Cre mice (Figure 7, A and B). Anti-GBM antibody and complement C3 were present in glomeruli of both M Cre and M + mice (Figure 7, C–F). There was slightly greater anti-GBM antibody immunofluorescence staining in M Cre mice but no difference in C3 deposition. Given that M Cre and M + mice were injected with the same dose of anti-GBM antibody in parallel, this apparently greater antibody localization in M Cre mice may be related to minor changes in collagen composition, which was already noted in older M Cre mice (Figure 2). Because glomerular deposition of C3 was the same in M Cre and M + mice, the exaggerated increase in albuminuria in the M Cre mice was most likely due to the podocyte IRE1α deletion. The C3 deposition in Bowman’s capsule is unrelated to anti-GBM antibody injection because C3 is known to be present in Bowman’s capsule of healthy mice (Ruseva ).
FIGURE 7:

Podocyte IRE1α deletion increases susceptibility to acute anti-GBM nephritis. (A) Male mice 5 mo of age were injected with 5 μl of sheep anti–GBM antibody (αGBM). Urine was collected preinjection and at 24 h. Kidneys were harvested at 24 h. In mice that received anti-GBM antibody, there was significantly greater albuminuria in the IRE1αflox/flox;Cre (M Cre) group than in controls (IRE1αflox/flox;+; M +). Albuminuria in anti-GBM M Cre mice was also significantly greater than the preinjection (baseline) value (*p = 0.005, ANOVA; N, number of animals). (B) The net change in albumin/creatinine ratio calculated per individual mouse for 10 anti-GBM injected M Cre mice and 6 injected M + mice was significantly greater in M Cre mice (*p = 0.049). (C–F) Anti-GBM antibody and C3 deposition in mouse glomeruli were confirmed by immunofluorescence microscopy. Quantification of sheep anti-GBM fluorescence intensity showed a slight increase in M Cre mice (*p = 4.27 × 10−7; 83 glomeruli from six GBM-injected M + mice and 110 glomeruli from seven GBM-injected M Cre mice). There were no significant differences in C3 deposition. C3 fluorescence intensity was measured in 80 glomeruli from six M + mice and 98 glomeruli from seven M Cre mice. Scale bars, 50 μm.

Podocyte IRE1α deletion increases susceptibility to acute anti-GBM nephritis. (A) Male mice 5 mo of age were injected with 5 μl of sheep anti–GBM antibody (αGBM). Urine was collected preinjection and at 24 h. Kidneys were harvested at 24 h. In mice that received anti-GBM antibody, there was significantly greater albuminuria in the IRE1αflox/flox;Cre (M Cre) group than in controls (IRE1αflox/flox;+; M +). Albuminuria in anti-GBM M Cre mice was also significantly greater than the preinjection (baseline) value (*p = 0.005, ANOVA; N, number of animals). (B) The net change in albumin/creatinine ratio calculated per individual mouse for 10 anti-GBM injected M Cre mice and 6 injected M + mice was significantly greater in M Cre mice (*p = 0.049). (C–F) Anti-GBM antibody and C3 deposition in mouse glomeruli were confirmed by immunofluorescence microscopy. Quantification of sheep anti-GBM fluorescence intensity showed a slight increase in M Cre mice (*p = 4.27 × 10−7; 83 glomeruli from six GBM-injected M + mice and 110 glomeruli from seven GBM-injected M Cre mice). There were no significant differences in C3 deposition. C3 fluorescence intensity was measured in 80 glomeruli from six M + mice and 98 glomeruli from seven M Cre mice. Scale bars, 50 μm. By electron microscopy, control M Cre mice and anti-GBM antibody-injected M + mice showed predominantly normal podocyte foot processes, with occasional focal effacement. In contrast, focal effacement was more abundant in anti–GBM-injected M Cre mice compared with injected M + mice (Figure 8, A and B). M Cre mice with anti-GBM nephritis also showed other ultrastructural signs of podocyte injury, such as podocyte basolateral plasma membranes completely fused to the GBM. In anti-GBM nephritis, M Cre mice exhibited a modest but significant podocyte loss, whereas there was no significant loss of podocytes in M + mice (Figure 8, C and D). Thus, in anti-GBM nephritis, podocyte-specific deletion of IRE1α exacerbated albuminuria, as well as podocyte loss and ultrastructural damage.
FIGURE 8:

Mice with podocyte deletion of IRE1α and anti-GBM nephritis exhibit podocyte loss and foot process effacement. (A) Representative electron micrographs showing mild foot-process widening in uninjected IRE1αflox/flox;Cre (M Cre) and injected IRE1αflox/flox;+ (M +) mice and greater widening in anti-GBM antibody–injected M Cre mice (24 h). (B) Quantification of images showing foot-process widening/effacement (N, number of animals). (C) Representative WT1 immunofluorescence images of mice with acute anti-GBM nephritis (24 h). Scale bar, 50 μm. (D) Quantification of WT1-positive cells shows that anti-GBM antibody treatment in M Cre mice resulted in a modest but significant loss of podocytes (*p = 0.027 anti-GBM vs. control in the M Cre groups). In M + mice, there was no significant decrease in podocytes after anti-GBM antibody.

Mice with podocyte deletion of IRE1α and anti-GBM nephritis exhibit podocyte loss and foot process effacement. (A) Representative electron micrographs showing mild foot-process widening in uninjected IRE1αflox/flox;Cre (M Cre) and injected IRE1αflox/flox;+ (M +) mice and greater widening in anti-GBM antibody–injected M Cre mice (24 h). (B) Quantification of images showing foot-process widening/effacement (N, number of animals). (C) Representative WT1 immunofluorescence images of mice with acute anti-GBM nephritis (24 h). Scale bar, 50 μm. (D) Quantification of WT1-positive cells shows that anti-GBM antibody treatment in M Cre mice resulted in a modest but significant loss of podocytes (*p = 0.027 anti-GBM vs. control in the M Cre groups). In M + mice, there was no significant decrease in podocytes after anti-GBM antibody.

IRE1α controls the physiological autophagosome formation rate

The foregoing studies in mice with podocyte-specific IRE1α RNase domain deletion showed that IRE1α contributes to maintenance of podocyte integrity in normal aging and glomerulonephritis. Moreover, IRE1α deletion appeared to disrupt autophagy in podocytes. To address the mechanism by which IRE1α regulates autophagy, we performed further studies in cultured cells. First, we overexpressed FLAG-IRE1α WT and several mutants in COS-1 cells by transient transfection and monitored IRE1α RNase activity with Xbp1 splicing in the presence of the ER stressor tunicamycin, using reverse transcriptase (RT)-PCR. Expression of IRE1α WT and the S724A phosphorylation-site mutant increased Xbp1 splicing beyond that caused by tunicamycin in control cells transfected with empty vector (Supplemental Figure S3). Expression of the K599A or ΔR mutants reduced tunicamycin-induced Xbp1 splicing, indicating that these two mutants act as dominant negative. We also tested the effect of the IRE1α RNase-directed inhibitor 4μ8C. During 6 h of cotreatment with tunicamycin, 4μ8C potently blocked Xbp1 splicing (Supplemental Figure S3). To confirm the role of IRE1α in regulating autophagy, we transiently transfected COS-1 cells with FLAG-IRE1α (WT, S724A, K599A, or ΔR) or empty vector. We changed culture medium after 22 h to remove residual transfection reagent, as well as to replenish amino acids and nutrients to ensure that experimental differences were not caused by starvation-induced autophagy. Then we treated cells with chloroquine to block degradation of autophagosomes and allow surface components (e.g., LC3B-II) and contents to accumulate in the cytoplasm (Tanida ; Ni ). Expression of FLAG-IRE1α WT and mutants is presented in Figure 9A. Densitometric quantification showed that expression of FLAG-IRE1α WT and K599A was comparable, whereas S724A and ΔR expression was 1.5-fold greater than WT (p < 0.0001; 24 experiments). The rate of autophagic vacuole formation/accumulation was determined by monitoring levels of LC3B-II, as LC3B-I levels were comparable in all cells. Basal LC3B-II accumulation was modest, as determined in cells transfected with empty vector, in the absence of chloroquine treatment, whereas chloroquine induced LC3B-II accumulation at 2 and 6 h (Figure 9, A and C). Overexpression of IRE1α WT and S724A slightly enhanced the rate of chloroquine-induced LC3B-II accumulation compared with chloroquine-treated vector-transfected cells, but this was not statistically significant (Figure 9, A and C). Conversely, overexpression of both dominant-negative mutants IRE1α K599A and ΔR significantly reduced the chloroquine-induced LC3B-II accumulation rate at 2 and 6 h compared with cells overexpressing IRE1α WT (Figure 9, A and C). In addition, IRE1α ΔR overexpression significantly reduced the accumulation rate compared with the empty vector transfection (chloroquine treated), and K599A tended to do so as well.
FIGURE 9:

IRE1α facilitates physiological formation of autophagic vacuoles. (A) COS-1 cells transiently transfected with vector (V), FLAG-IRE1α WT, or mutants were treated with or without chloroquine (CQ, 50 μM). Levels of LC3B were measured by immunoblotting after 2 or 6 h. FLAG-IRE1α expression was confirmed using anti-FLAG antibody. (C) Quantification of the rate of LC3B-II accumulation shows that overexpression of IRE1α K599A and ΔR significantly reduces the formation of LC3B-II vs. IRE1α WT. IRE1α ΔR also significantly lowers the rate of LC3B-II formation vs. control (vector), whereas IRE1α K599A tends to lower the rate of formation vs. control (*p = 5.40 × 10−7 [IRE1α]; p = 1.09 × 10−9 [CQ]; p < 2.2 × 10−16 [time]; p = 0.0018 [IRE1α × time interaction]; p = 1.07 × 10−4 [CQ × time interaction]; seven experiments). (B) COS-1 cells transfected with vector (V), IRE1α WT, or K599A were treated with chloroquine (CQ, 50 μM) plus vehicle (DMSO [D]) or MG132 (MG, 25 μM). Overexpression of IRE1α K599A reduced the rate of LC3B-II accumulation independently of MG132 treatment. (D) Quantification of the rate of LC3B-II accumulation over the 6-h chloroquine treatment period shows that overexpression of IRE1α K599A significantly reduced the rate of LC3B-II accumulation vs. control (empty vector) and vs. IRE1α WT. Differences were significant at 2 h and increased further at 6 h (*p = 0.0047 [IRE1α]; p = 1.1 × 10−14 [time]). These effects were independent of MG132. Six experiments.

IRE1α facilitates physiological formation of autophagic vacuoles. (A) COS-1 cells transiently transfected with vector (V), FLAG-IRE1α WT, or mutants were treated with or without chloroquine (CQ, 50 μM). Levels of LC3B were measured by immunoblotting after 2 or 6 h. FLAG-IRE1α expression was confirmed using anti-FLAG antibody. (C) Quantification of the rate of LC3B-II accumulation shows that overexpression of IRE1α K599A and ΔR significantly reduces the formation of LC3B-II vs. IRE1α WT. IRE1α ΔR also significantly lowers the rate of LC3B-II formation vs. control (vector), whereas IRE1α K599A tends to lower the rate of formation vs. control (*p = 5.40 × 10−7 [IRE1α]; p = 1.09 × 10−9 [CQ]; p < 2.2 × 10−16 [time]; p = 0.0018 [IRE1α × time interaction]; p = 1.07 × 10−4 [CQ × time interaction]; seven experiments). (B) COS-1 cells transfected with vector (V), IRE1α WT, or K599A were treated with chloroquine (CQ, 50 μM) plus vehicle (DMSO [D]) or MG132 (MG, 25 μM). Overexpression of IRE1α K599A reduced the rate of LC3B-II accumulation independently of MG132 treatment. (D) Quantification of the rate of LC3B-II accumulation over the 6-h chloroquine treatment period shows that overexpression of IRE1α K599A significantly reduced the rate of LC3B-II accumulation vs. control (empty vector) and vs. IRE1α WT. Differences were significant at 2 h and increased further at 6 h (*p = 0.0047 [IRE1α]; p = 1.1 × 10−14 [time]). These effects were independent of MG132. Six experiments. It has been reported that inhibition of the proteasome can enhance accumulation of autophagosomes (Ding ; Wang ). In the next study, we examined whether proteasomal inhibition can stimulate autophagy during the same experimental time course as the one that revealed involvement of IRE1α. Cells expressing vector, FLAG-IRE1α WT, or K599A were cotreated with chloroquine and either vehicle (dimethyl sulfoxide [DMSO]) or 25 μM MG132. LC3B-II accumulation increased at 2 and 6 h in all groups, but the increase in LC3B-II was significantly lower at both time points in the IRE1α K599A group (Figure 9, B and D). MG132 tended to increase LC3B-II at 2 and 6 h in each of the three groups, but differences between MG132- and vehicle-treated cells were not statistically significant (Figure 9, B and D). We also conducted separate experiments to verify that MG132 cannot itself modulate the autophagosome formation rate in COS-1 cells. After 6 h of incubation, neither 25 μM MG132 treatment alone nor MG132 cotreatment with chloroquine could potentiate the autophagosome formation rate beyond that caused by chloroquine alone (unpublished data).

IRE1α determines the volume rather than the number of autophagosomes

To extend our investigation of the effects of IRE1α on LC3-II levels, we studied formation of LC3B-II–positive autophagosomes (autophagic “puncta”) in COS-1 cells by monitoring mCherry–enhanced green fluorescent protein (eGFP)–LC3B fluorescence (N’Diaye ; Mizushima ). mCherry-eGFP-LC3B-I is expressed diffusely in the cytoplasm; however, after induction of autophagy, mCherry-eGFP-LC3B-II binds to the surface of the autophagosomes, giving bright puncta that are dually mCherry and eGFP fluorescent. eGFP is quenched in the acidic lysosomes, whereas mCherry is acid stable; therefore eGFP-mCherry–positive puncta are autopha­gosomes or autolysosomes deacidified by chloroquine, whereas mCherry-positive puncta are active lysosomes or autolysosomes. COS-1 cells grown on collagen-coated coverslips were cotransfected with FLAG-IRE1α (WT, S724A, K599A, or ΔR) or empty vector, along with mCherry-eGFP-LC3B (Figure 10, A–C). Cells were either untreated or treated with chloroquine. Quantifying only the eGFP fluorescence of puncta that colocalized with mCherry allowed us to monitor autophagic puncta independent of lysosomes, autolysosomes, diffuse LC3B-I and green-channel autofluorescence. Puncta area increased in the presence of chloroquine in vector-, IRE1α WT–, and S724A-transfected cells. Compared with these groups, both the K599A and ΔR mutants reduced the cell area occupied by autophagic puncta (Figure 10, A and B). Increased puncta area was largely explained by increased puncta size (Figure 10C) and not number of puncta. Immunofluorescence using FLAG antibody revealed FLAG-IRE1α WT and mutants in respective transfected cells, with robust perinuclear expression of IRE1α and, to a lesser extent, filamentous-cytoplasmic expression, as expected for an ER transmembrane protein (Figure 12D).
FIGURE 10:

IRE1α modulates autophagosome volume. (A) COS-1 cells were transiently cotransfected with FLAG-IRE1α WT or mutants and mCherry-eGFP-LC3B. Cells were untreated or treated with chloroquine (CQ, 50 μM) and examined after 6 h. The mCherry-eGFP-LC3B reporter was not transfected in the cells shown in the first row (negative control). (B) Quantification revealed that the punctal area (the cross-sectional area occupied by autophagic puncta per 1000 μm2 of total cell area) was lower in chloroquine-treated K599A- and ΔR-overexpressing cells compared with treated WT or vector/control (*p = 1.11 × 10−10 [IRE1α]; p < 2.2 × 10−16 [CQ]; p = 4.19 × 10−8 [IRE1α × CQ interaction]). (C) Cross-sectional area per autophagosome (punctum size) paralleled punctal area. IRE1α WT or S724A increased punctum size compared with control, K599A, or ΔR (*p = 4.20 × 10−5 [IRE1α]; p < 2.2 × 10−16 [CQ]; p = 7.82 × 10−3 [IRE1α × CQ interaction]). (D) Cells expressing empty vector or FLAG-IRE1α WT or mutants were immunostained with anti-FLAG antibody (nonimmune IgG in controls). IRE1α WT. and mutants show cytoplasmic staining with perinuclear accentuation. For B and C, the number of trials and the number of quantified cells are indicated beneath columns.

FIGURE 12:

Dominant-negative IRE1α mutants (K599A and ΔR) accelerate degradation of CD3δ-YFP. (A) COS-1 cells cotransfected with FLAG-IRE1α (WT or mutants) and the ERAD reporter CD3δ-YFP were pretreated with MG132 (MG, 10 μM) to partially block the proteasome. At 2 h, vehicle (DMSO) or cycloheximide (CX, 25 μg/ml) was added. Lysates were immunoblotted after another 2 or 6 h, as indicated. Expression of IRE1α and CD3δ-YFP was confirmed using anti-FLAG and anti-GFP antibodies, respectively. Overexpression of IRE1α K599A or ΔR enhanced CD3δ-YFP degradation. The lane labeled “–” is a mock-transfected, cycloheximide-treated control sample, which confirms the CD3δ-YFP signal specificity. (B) Densitometric quantification showed that in the presence of cycloheximide, overexpression of IRE1α K599A or ΔR enhanced CD3δ-YFP degradation compared with vector. In addition, IRE1α K599A enhanced CD3δ-YFP degradation compared with WT (*p = 0.003 [IRE1α]; p = 0.0065 [CX]; p = 0.003 [IRE1α × time interaction; five experiments]. (C) COS-1 cells coexpressing IRE1α WT and CD3δ-YFP were cotreated with cycloheximide together with either vehicle (DMSO [D]) or tunicamycin (Tm or T, 5 μg/ml). Lysates were immunoblotted 2, 4, and 8 h posttreatment. The lanes labeled “V only” are without transfection of CD3δ-YFP. (D) Densitometric quantification shows that tunicamycin stimulated degradation of CD3δ-YFP in vector- and IRE1α-transfected cells. IRE1α did not modulate the tunicamycin-induced degradation of CD3δ-YFP, that is, overexpression of IRE1α WT did not potentiate tunicamycin-induced degradation of CD3δ-YFP, nor did IRE1α K599A exert an inhibitory effect (*p = 4.12 × 10−5 [Tm]; p = 3.70 × 10−15 [CX + time]; six experiments).

IRE1α modulates autophagosome volume. (A) COS-1 cells were transiently cotransfected with FLAG-IRE1α WT or mutants and mCherry-eGFP-LC3B. Cells were untreated or treated with chloroquine (CQ, 50 μM) and examined after 6 h. The mCherry-eGFP-LC3B reporter was not transfected in the cells shown in the first row (negative control). (B) Quantification revealed that the punctal area (the cross-sectional area occupied by autophagic puncta per 1000 μm2 of total cell area) was lower in chloroquine-treated K599A- and ΔR-overexpressing cells compared with treated WT or vector/control (*p = 1.11 × 10−10 [IRE1α]; p < 2.2 × 10−16 [CQ]; p = 4.19 × 10−8 [IRE1α × CQ interaction]). (C) Cross-sectional area per autophagosome (punctum size) paralleled punctal area. IRE1α WT or S724A increased punctum size compared with control, K599A, or ΔR (*p = 4.20 × 10−5 [IRE1α]; p < 2.2 × 10−16 [CQ]; p = 7.82 × 10−3 [IRE1α × CQ interaction]). (D) Cells expressing empty vector or FLAG-IRE1α WT or mutants were immunostained with anti-FLAG antibody (nonimmune IgG in controls). IRE1α WT. and mutants show cytoplasmic staining with perinuclear accentuation. For B and C, the number of trials and the number of quantified cells are indicated beneath columns.

Induction of autophagy via IRE1α does not require IRE1α RNase activity

Given that IRE1α K599A (a kinase- and RNase-inactive mutant) and ΔR (RNase-domain deletion mutant that can bind ATP) both reduced the autophagosome formation rate (Figure 9), we then determined whether this process requires the physical presence of the RNase domain or RNase activity. COS-1 cells were cotreated with chloroquine plus vehicle or the IRE1α RNase inhibitor 4μ8C. Over a 24-h period, 4μ8C had no significant effect on the LC3B-II accumulation rate (Figure 11A). In addition, there were no differences in either the LC3B-II/I ratio or the LC3B-II/actin ratio (Figure 11, C and D). To validate that 4μ8C inhibited IRE1α RNase activity effectively, we coincubated cells with 4μ8C and tunicamycin and demonstrated that 4μ8C abolished tunicamycin-induced Xbp1 splicing (Figure 11B). Therefore these data strongly suggest that autophagosome formation requires IRE1α kinase activity and the presence of the C-terminal RNase domain (perhaps a protein-binding site) but not IRE1α RNase activity. Note that IRE1α WT can potentially induce IRE1α clusterization, resulting in Xbp1 splicing under unstressed conditions. Such an effect cannot be entirely excluded under these experimental conditions.
FIGURE 11:

IRE1α-mediated autophagosome formation does not require RNase activity. (A) COS-1 cells were treated with chloroquine (CQ, 50 μM), the IRE1α RNase inhibitor 4μ8c (10 μM), or vehicle (DMSO). Quantification of the rate of autophagosome formation for up to 24 h as reported by LC3B-II normalized to actin (C) or the LC3B-II to I ratio (D) revealed no significant differences in the presence or absence of 4μ8c, although LC3B-II increased over time (C: p = 2.21 × 10−6; D: p = 9.34 × 10−5; three experiments). (B) Tunicamycin (T, 10 μg/ml) induced Xbp1 splicing, and this effect was blocked by 4μ8c (4μ, 10 μM) at 6 and 24 h. NR, no–reverse transcriptase negative control; NT, no-template negative control; Tx, treatment.

IRE1α-mediated autophagosome formation does not require RNase activity. (A) COS-1 cells were treated with chloroquine (CQ, 50 μM), the IRE1α RNase inhibitor 4μ8c (10 μM), or vehicle (DMSO). Quantification of the rate of autophagosome formation for up to 24 h as reported by LC3B-II normalized to actin (C) or the LC3B-II to I ratio (D) revealed no significant differences in the presence or absence of 4μ8c, although LC3B-II increased over time (C: p = 2.21 × 10−6; D: p = 9.34 × 10−5; three experiments). (B) Tunicamycin (T, 10 μg/ml) induced Xbp1 splicing, and this effect was blocked by 4μ8c (4μ, 10 μM) at 6 and 24 h. NR, no–reverse transcriptase negative control; NT, no-template negative control; Tx, treatment.

Inhibition of IRE1α permits substrate shunting into ERAD

Our findings implicated a role for IRE1α in mediating basal autophagic flux. However, besides autophagy, IRE1α has been linked to ERAD. Thus we examined whether degradation of ER misfolded proteins also involves IRE1α-dependent ERAD or autophagy-ERAD cross-talk. Degradation of ectopically expressed CD3δ–yellow fluorescent protein (YFP) in the presence of cycloheximide (to block protein synthesis) was used to monitor ERAD (Menendez-Benito ). CD3δ-YFP is retrotranslocated from the ER into the cytoplasm and then degraded by the proteasome. COS-1 cells were cotransfected with CD3δ-YFP and IRE1α, and, after 24 h, they were treated with cycloheximide for 6 h. Over the 6-h period, the amount of CD3δ-YFP decreased by ∼40% (similar to the results shown in Figure 12D, vector/DMSO group). Neither IRE1α WT nor K599A overexpression affected the rate of CD3δ-YFP degradation compared with control (similar to Figure 12D). We next examined whether IRE1α can modulate ERAD in the presence of reduced proteasomal capacity (partial inhibition of the proteasome with MG132). COS-1 cells were cotransfected with CD3δ-YFP and IRE1α WT, S724A, K599A, ΔR, or empty vector (Figure 12A). After 24 h, cells were treated for 2 h with a low dose of MG132 (10 μM) to partially inhibit the proteasome and allow for CD3δ-YFP accumulation. Then cycloheximide was added to inhibit protein synthesis. In the presence of low-dose MG132, the level of CD3δ-YFP was near constant over time in cycloheximide-treated cells that had been cotransfected with empty vector or IRE1α WT (Figure 12, A and B). This result was predicted for the empty vector control because MG132 would partially inhibit proteasomal degradation of CD3δ-YFP. Overexpression of IRE1α WT did not overcome partial proteasomal blockade by promoting degradation of CD3δ-YFP, indicating that IRE1α was unable to enhance ERAD. However, overexpression of both K599A and ΔR mutants significantly enhanced degradation of CD3δ-YFP (Figure 12, A and B) while blocking autophagic flux at comparable time points (Figure 9C). IRE1α S724A overexpression mildly enhanced degradation of CD3δ-YFP, although this effect was not statistically significant (Figure 12B). Note that the level of CD3δ-YFP tended to increase in the absence of cycloheximide in control cells (Figure 12B), suggesting that there was ongoing synthesis of the reporter; consequently, all of the effects of IRE1α WT and mutants on CD3δ-YFP were studied in the presence of cycloheximide, where changes in CD3δ-YFP reflect degradation. Together, these results are in keeping with the view that under basal conditions, IRE1α is a positive regulator of autophagy but not ERAD. Also note that partial inhibition of proteasomal activity with a low dose of MG132 was required to observe enhancement of ERAD by the K599A and ΔR mutants. Dominant-negative IRE1α mutants (K599A and ΔR) accelerate degradation of CD3δ-YFP. (A) COS-1 cells cotransfected with FLAG-IRE1α (WT or mutants) and the ERAD reporter CD3δ-YFP were pretreated with MG132 (MG, 10 μM) to partially block the proteasome. At 2 h, vehicle (DMSO) or cycloheximide (CX, 25 μg/ml) was added. Lysates were immunoblotted after another 2 or 6 h, as indicated. Expression of IRE1α and CD3δ-YFP was confirmed using anti-FLAG and anti-GFP antibodies, respectively. Overexpression of IRE1α K599A or ΔR enhanced CD3δ-YFP degradation. The lane labeled “–” is a mock-transfected, cycloheximide-treated control sample, which confirms the CD3δ-YFP signal specificity. (B) Densitometric quantification showed that in the presence of cycloheximide, overexpression of IRE1α K599A or ΔR enhanced CD3δ-YFP degradation compared with vector. In addition, IRE1α K599A enhanced CD3δ-YFP degradation compared with WT (*p = 0.003 [IRE1α]; p = 0.0065 [CX]; p = 0.003 [IRE1α × time interaction; five experiments]. (C) COS-1 cells coexpressing IRE1α WT and CD3δ-YFP were cotreated with cycloheximide together with either vehicle (DMSO [D]) or tunicamycin (Tm or T, 5 μg/ml). Lysates were immunoblotted 2, 4, and 8 h posttreatment. The lanes labeled “V only” are without transfection of CD3δ-YFP. (D) Densitometric quantification shows that tunicamycin stimulated degradation of CD3δ-YFP in vector- and IRE1α-transfected cells. IRE1α did not modulate the tunicamycin-induced degradation of CD3δ-YFP, that is, overexpression of IRE1α WT did not potentiate tunicamycin-induced degradation of CD3δ-YFP, nor did IRE1α K599A exert an inhibitory effect (*p = 4.12 × 10−5 [Tm]; p = 3.70 × 10−15 [CX + time]; six experiments).

Tunicamycin enhances ERAD independently of IRE1α

In this experiment, we investigated the regulatory role of IRE1α in cells subjected to ER stress induced by tunicamycin. In a preliminary study, we found that 6-h incubation with 5 μg/ml tunicamycin potently blocked CD3δ-YFP glycosylation (unpublished data), consistent with induction of protein misfolding and ER stress. COS-1 cells were cotransfected with IRE1α (WT or K599A) or empty vector together with CD3δ-YFP to monitor ERAD. After 24 h, cells were treated for 2 h with either vehicle (DMSO) or 5 μg/ml tunicamycin plus cycloheximide to simultaneously induce ER protein misfolding while inhibiting protein synthesis. Tunicamycin treatment in all cells significantly enhanced the degradation of CD3δ-YFP, but this was not affected by IRE1α WT or K599A (Figure 12, C and D). Thus ERAD can be up-regulated secondary to misfolded protein accumulation; however, this occurs independently of ectopic IRE1α overexpression or inhibition of endogenous IRE1α.

DISCUSSION

Overall our study demonstrates the importance of physiological IRE1α activity in podocyte homeostasis and establishes an important link between IRE1α and autophagy. Deletion of the IRE1α RNase domain in podocytes in vivo induced podocyte injury and perturbed glomerular capillary wall integrity during the aging process (Figures 1 and 3) and in acute glomerulonephritis (Figures 7 and 8). Moreover, deletion of IRE1α in podocytes resulted in glomerular volume expansion (in particular, capillary volume), relative podocyte depletion, reduction of synaptopodin, and enhanced collagen deposition (Figures 2 and 4). In keeping with an earlier study on podocyte-specific Atg5 deletion in mice (Hartleben ), the deletion of IRE1α in podocytes, together with our findings in cell culture, links podocyte autophagy flux with global glomerular health as mice age. In 5- to 13-mo podocyte-specific IRE1α-deficient mice, albuminuria was observed in males but not females (Figure 1). This gender-specific difference may result from genetic determinants in mouse glomerular physiology. In general, male mice have a higher basal albumin/creatinine ratio than females. This might be due to gender-specific differences in basal intraglomerular capillary pressure, including differences in sensitivity to angiotensin II and/or norepinephrine at the glomerular afferent and efferent arterioles. Alternatively, gender-specific differences may determine the nature of cross-talk between podocytes and glomerular endothelial cells, perhaps involving vascular endothelial growth factor and/or nitric oxide, which are factors known to mediate vascular dilation (Tryggvason and Wartiovaara, 2001; Chiang and Inagi, 2010; Greka and Mundel, 2012; Welsh and Saleem, 2012; Brinkkoetter ). IRE1α in podocytes may be involved in the regulation of intraglomerular hemodynamic forces that exert outward hydrostatic pressure from within the glomerular capillaries, as well as glomerular capillary structure and volume. In podocyte-specific IRE1α-deficient males, intraglomerular structural changes were observed, such as dilated glomerular capillaries, glomerular volume expansion, and enhanced collagen deposition in the glomerulus. Such perturbations could lead to age-dependent capillary wall weakening and distension of podocytes, eventually leading to podocyte detachment. Deposition of collagen in the glomerulus could represent a compensatory response for structural deficiency, eventually leading to glomerulosclerosis. Indeed, deposition of collagen in the mesangial regions of glomeruli most likely reflects early glomerulosclerosis. Within this context, the precise mechanism underlying podocyte-mediated capillary dilation in the absence of IRE1α remains to be established. In association with albuminuria, podocyte-specific IRE1α deletion resulted in ultrastructural changes of injury and dedifferentiation, including microvillous transformation of plasma membranes, formation of occludens junctions, and focal effacement of foot processes (Figure 3). When the WT1 counts are taken together with evidence of glomerular volume expansion (Figure 2) and the relative depletion of the podocyte marker synaptopodin (Figure 4), the same number of podocytes would reside upon volume-expanded glomerular capillaries, that is, fewer podocytes per unit glomerular volume, implying relative podocyte depletion (Puelles and Bertram, 2015). Remaining podocytes would stretch and hypertrophy. Over time, the relative podocyte depletion would lead to injury, as reflected by the ultrastructural changes. Before the onset of albuminuria, podocyte-specific, IRE1α-deficient young male mice showed increased susceptibility to develop acute anti-GBM nephritis. At the low dose of anti-GBM antibody we used, IRE1α-sufficient mice did not develop a significant increase in the urine albumin/creatinine ratio. In contrast, the podocyte-specific, IRE1α-deficient mice exhibited a fourfold rise in this ratio above the preinjection (baseline) ratio and approximately threefold increase versus the control group (Figure 7). Podocyte-specific, IRE1α-deficient mice with anti-GBM nephritis also displayed evidence of severe foot process effacement and loss of podocytes compared with the control group (Figure 8). This result indicates that IRE1α is important in the maintenance of podocyte structure and glomerular permselectivity not only during aging, but also in response to acute glomerular injury. Before the onset of albuminuria, male podocyte-specific, IRE1α-deficient mice showed glomerular UPR activation (increases in Grp78 and Grp94), accumulation of polyubiquitinated proteins, and deficient autophagosome turnover (Figure 5). After the onset of podocyte injury and albuminuria (at 9 mo of age), evidence of UPR activation and accumulation of polyubiquitinated proteins was absent in podocyte-specific, IRE1α-deficient mice compared with control mice, whereas the defect in autophagy persisted (Figure 6). The ER stress response in the prealbuminuric, podocyte-specific, IRE1α-deficient mice may have been induced by another branch of the UPR, perhaps the ATF6 pathway. By 9 mo of age, enhancement of ERAD in the podocyte-specific, IRE1α-deficient mice may have attenuated the UPR response by eliminating the accumulated polyubiquitinated proteins (despite deficient autophagy). Our finding in cell culture that inhibition of IRE1α by the IRE1α ΔR mutant permits substrate shunting into the ERAD pathway supports this possibility (Figure 12). The mechanism by which IRE1α maintains podocyte homeostasis and glomerular integrity as mice age, involves autophagy, at least in part (Figures 5 and 6). IRE1α can bind TRAF2 and activate ASK1, which in turn can activate JNK1 and beclin-1 to stimulate autophagy (Nishitoh ). The reduced activation-specific phosphorylation of JNK1 in glomeruli of mice with podocyte-specific IRE1α deletion supports the role of JNK1 as a mediator of autophagy (Figure 6); however, the pathway will require further elucidation, as JNK1 phosphorylation was not reduced significantly in prealbuminuric mice, despite reduced autophagy (Figure 5). Podocytes display a relatively higher basal rate of autophagy compared with other cells, and based on studies in podocyte-specific, Atg5 KO mice, autophagy appears to be a homeostatic mechanism to maintain podocyte integrity and a protective mechanism against aging and glomerular injury (Hartleben ; Kawakami ). Thus the Atg5 KO mice developed focal and global glomerulosclerosis by 22 mo of age (Hartleben ). Impaired autophagy in podocyte-specific, IRE1α-deficient mice may perturb the synthesis and delivery of key structural proteins required for slit diaphragm assembly or podocyte–GBM interactions. Alternatively, impaired autophagy could affect the production of secreted factors necessary for maintenance of glomerular structure, such as vascular endothelial growth factor. There are some limitations to quantifying enhanced autophagic flux in vivo. Thus, to confirm the role of IRE1α in autophagy, we measured the conversion of LC3-I to LC3-II in cultured cells expressing IRE1α WT and various mutants. Our results indicate that IRE1α constitutively regulates formation of autophagosomes—specifically, their volume (Figures 9 and 10). Overexpression of two dominant-negative IRE1α mutants (K599A and ΔR) reduced the mean cross-sectional area of autophagosomes by ∼30%, compared with IRE1α WT. In terms of autophagosome volume, this translates into a ∼40% reduction. Of interest, the effect of IRE1α on formation of autophagosomes required both the IRE1α kinase and RNase domains but not RNase activity (Figures 9– 11). Therefore IRE1α activation through the RNase-independent activation of the ASK1-TRAF2-JNK signaling pathway (Kaneko ) could promote an ER framework (“cradle”) for autophagosome formation (Hayashi-Nishino ; Yla-Anttila ). Alternatively, IRE1α is believed to up-regulate the expression of factors that mediate ERAD (Hetz and Soto, 2003; Hetz and Glimcher, 2009), although a link between IRE1α and ERAD has not been established conclusively (Chiang ; Sun ). In the present study, overexpression of both IRE1α K599A and ΔR mutants in cultured cells significantly enhanced degradation of the ERAD reporter CD3δ-YFP while blocking autophagic flux (Figures 9 and 12). These results are in keeping with the view that IRE1α is a positive regulator of autophagy but not of ERAD. Indeed, IRE1α might constitutively inhibit ERAD via ASK1-mediated Rpt5 phosphorylation in the 19S regulatory cap of the 26S proteasome (Um ). Given the lack of an ERAD-specific endogenous reporter in the mouse glomerulus, we cannot make definite conclusions on the potential role of IRE1α in ERAD in vivo. Recently mice with podocyte-specific deletion of Xbp1 were characterized (Hassan ). In contrast to the podocyte-specific deletion of IRE1α, podocyte Xbp1-deficient mice displayed no proteinuria or histological evidence of glomerular injury up to 1 yr of age. However, when deletion of Xbp1 was combined with podocyte-specific deletion of Sec 63 (a chaperone required for protein folding in the ER), the double-deletion mice developed albuminuria by 8–10 wk of age, which continued to progress over a 1-yr period. There were associated ultrastructural changes in the podocytes, glomerulosclerosis, and apoptosis of podocytes, which correlated with activation of JNK and caspases. These results suggest that deletion of Xbp1 and Sec 63 resulted in overactivation of IRE1α and consequently a cytotoxic UPR. In summary, the present study provides important functional information on the contribution of IRE1α to podocyte homeostasis and injury. We expect that our findings will enhance interest in testing compounds that modulate IRE1α for their therapeutic protective effects on podocyte injury and glomerulonephritis.

MATERIALS AND METHODS

Reagents and antibodies

Cell culture reagents were purchased from Wisent (Saint-Jean-Baptiste, Canada). Electrophoresis and immunoblotting reagents were from Bio-Rad Laboratories (Mississauga, Canada), Sigma-Aldrich (St. Louis, MO), Thermo Fisher Scientific (Burlington, Canada), and Amersham GE Healthcare (Baie d’Urfé, Canada). Lipofectamine 2000 and OptiMEM were from Invitrogen Life Technologies (Burlington, Canada). Rabbit monoclonal anti–phospho-JNK (4668S), rabbit anti-JNK (9252S), rabbit anti-LC3B (2775S), rabbit anti–beclin-1 (3495), rabbit anti-Atg3 (3415), and rabbit anti-Atg5 (12994) were from Cell Signaling Technology (Danvers, MA). Mouse anti-GFP B-2 (sc-9996), rat anti-Grp94 9G10 (sc-32249), goat anti–synaptopodin P-19 (sc-21537), rabbit anti-WT1 C-19 (sc-192), and mouse anti-CHOP (sc-7357) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-podocalyxin (AF1556) was purchased from R & D systems (Minneapolis, MN). Mouse M2 anti-FLAG (F3165 or F1804), rabbit anti-ubiquitin (U5379), and rabbit anti-actin (A2066) antibodies were purchased from Sigma-Aldrich. Rabbit anti-Grp78 antibody (SPA-826) was purchased from Enzo Life Sciences (Ann Arbor, MI). Rabbit anti–phospho-eIF2α Ser51 (44728G) was from Invitrogen. Rabbit anti-nephrin antiserum was kindly provided by Tomoko Takano (McGill University, Montreal, Canada) and was described previously (Elimam ). Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse complement C3 antibody (Cappel 55500) and rabbit anti-sheep immunoglobulin G (IgG; 0865205) were purchased from MP Biomedicals (Santa Ana, CA).

Plasmids

Plasmids encoding full-length IRE1α WT or S724A, K599A or RNase-deletion (ΔR) mutants in-frame with a C-terminal FLAG epitope tag were kindly provided by Yong Liu (Shanghai Institutes for Biological Sciences, Shanghai, China; Qiu ). The plasmid encoding CD3δ-YFP was described previously (Menendez-Benito ). pBABE-puro-mCherry-eGFP-LC3B was purchased from Addgene (plasmid 22418). pRC/RSV empty vector (Invitrogen) was used as a mock-transfection control. Plasmid identities were confirmed by restriction digestion analyses and DNA sequencing.

Cell culture and transfection

Kidney fibroblastic COS-1 cells were cultured in DMEM with 10% fetal bovine serum. Cells were used between passages 4 and 50. For immunoblot studies, 2 × 105 cells were plated into 35-mm plates in 2 ml of medium. To prepare cells on coverslips for microscopy studies of autophagic puncta, 5 × 104 cells were plated in 22-mm wells on bovine collagen–coated coverslips in 1 ml of culture medium. Cells were grown at 37°C in 5% CO2 and constant humidity until ∼70% confluency. Cells were transiently transfected with plasmid DNAs using Lipofectamine 2000 according to the manufacturer’s instructions. For experiments, culture medium was replaced 22 h posttransfection with fresh medium (37°C) to prevent starvation-mediated autophagy and remove residual transfection reagents. Experiments were initiated after 2 h. For immunoblotting studies, transfections involved 1 μg of IRE1α-FLAG or pRC/RSV, which was combined with 1 μg CD3δ-YFP in studies of ERAD. For fluorescence microscopy, transfections involved 0.3 μg of pBABE-puro-mCherry-eGFP-LC3B plasmid, 0.5 μg of pRC/RSV, or 0.5 μg of IRE1α.

Mouse breeding and genotyping

IRE1α flox/flox mice (loxP sites surrounding IRE1α exons 20 and 21) maintained on a C57BL/6 and 129 mixed background were generated as described previously (Iwawaki ). The IRE1α flox/flox mice were crossed with podocin-Cre/+ mice of a mixed ICR/129/B6 background in the F0 generation to give F1 podocin-Cre/+; IRE1α flox/+ mice. F1 mice were backcrossed with F0 IRE1α flox/flox mice to give 25% podocin-Cre/+; IRE1α flox/flox mice, 25% podocin-Cre/+; IRE1α flox/+ mice, 25% +/+; IRE1α flox/flox mice, and 25% +/+; IRE1α flox/+ mice in the F2 generation. Thereafter F2 podocin-Cre/+; IRE1α flox/flox males were crossed with F2 +/+; IRE1α flox/flox females to give F3 littermates that were 50% podocin-Cre/+; IRE1α flox/flox and 50% +/+; IRE1α flox/flox. Animal protocols were reviewed and approved by the McGill University Animal Care Committee. For genotyping, PCR was conducted on tail DNA, which was extracted after a 1 h digestion with proteinase K. The podocin-Cre allele was amplified with forward primer 5′-CGTACTGACGGTGGGAGAAT-3′ and reverse primer 5′-TGCATGATCTCCGGTATTGA-3′, resulting in a 374–base pair product. The IRE1α WT and flox alleles were amplified with forward primer 5′-CCGAGCCATGAGAAACAAGG-3′ and reverse primer 5′-CCCTGCCAGGATGGTCATGG-3′. The WT allele appeared as a 254–base pair band, and the floxed allele appeared as a 229–base pair band. To confirm podocyte IRE1α deletion, glomeruli were isolated from mouse kidneys by differential sieving as described previously (Salant and Cybulsky, 1988), and genomic DNA was purified. PCR primers were designed to amplify a 1025–base pair unspliced loxP allele and a 189–base pair deletion product that results from Cre-dependent excision of IRE1α exons 20 and 21, with both primers flanking the loxP sites that surround IRE1α exons 20 and 21: forward 5′-CCAGTGCTCTTGAAAAGAGG-3′ and reverse 5′-CCCTGCCAGGATGGTCATGG-3′. In parallel, this PCR program was used to amplify the 374–base pair product of the glomerular podocin-Cre gene, using the same primers as described.

Anti-GBM nephritis

Sheep anti-rat GBM antiserum production was described previously (Salant and Cybulsky, 1988). Mice were injected intravenously with 5 μl of antiserum (Salant and Cybulsky, 1988). In preliminary studies, we established that the 5-μl dose of antibody induced modest albuminuria.

Measurement of urinary albumin, creatinine, and serum creatinine

Spot urine samples were collected from mice in the morning, immediately placed on ice, and subsequently frozen. Urinary albumin concentration was measured using the Mouse Albumin ELISA Quantification Kit (Bethyl Laboratories, Montgomery, TX) according to the manufacturer’s instructions. Urinary creatinine was measured using a creatinine assay kit from Cayman Chemical Company (Ann Arbor, MI). The kit uses a picric acid–based method. All samples were analyzed at least in duplicate. Albumin and creatinine concentrations were obtained using the standard curve equation of best fit, and the albumin/creatinine ratio was calculated in micrograms/milligram for each animal. For serum creatinine, mice were exsanguinated by cardiac puncture. Serum creatinine was measured using an enzymatic assay on the Olympus AU5822 chemistry system (Beckman Coulter) in the Biochemistry Laboratory at the McGill University Health Centre.

Immunoblotting

COS-1 cells and isolated mouse glomeruli were lysed in buffer containing 1% Triton X-100 (lysis buffer) supplemented with 10 μl/ml protease inhibitor cocktail (BioShop) as described previously (Elimam ). Cytosolic protein concentrations were measured with the Bradford assay. Samples were subjected to SDS–PAGE, and proteins were electrophoretically transferred to a polyvinylidene fluoride membrane of 0.2 μm pore size. Membranes were blocked in a solution of 5% bovine serum albumin (BSA) in 1× Tris-buffered saline supplemented with 0.1% Tween-20 (1× TTBS). Membranes were then incubated in primary antibody in 5% BSA in 1× TTBS, overnight, followed by incubation in horseradish peroxidase–conjugated secondary antibody for 1 h at 22°C.

Reverse transcriptase-PCR for Xbp1

Cells were lysed, and mRNA was purified using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Purified mRNA integrity was verified using electrophoresis. Bands were assessed for the integrity of rRNA under ultraviolet light. Xbp1 forward and reverse primers flanked the 26-nucleotide region that is normally spliced and excised by IRE1α. Xbp1 forward primer was 5′-CCAAAAACTTTTGCTAGAAAATCA-3′, and the reverse primer was 5′-CAGAATCCATGGGGAGATGT-3′.

Histology and light microscopy

At the time of kidney harvesting, segments of renal cortex were collected on ice, cut to 1.5 mm × 2 mm rectangular blocks with the cortical-to-medullary (apical-to-distal) axis lengthwise, and fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS). Tissues were paraffin embedded, sectioned at 3–4 μm thickness, and stained with PAS or Jones’ silver stain. Kidney sections were examined using a Zeiss AXIO Observer.Z1 microscope. Images were collected with a Zeiss AxioCam MRm monochrome camera (Carl Zeiss, Oberkochen, Germany) at an exposure length set to avoid camera saturation. For PAS- and Jones’ silver–stained glomeruli, cross-sectional area was measured in ImageJ as follows. Using the “freehand shape” tool, a glomerulus was outlined, and cross-sectional area in micrometers squared was obtained using the “measure” tool. To determine the fraction of a glomerular cross-section occupied by glomerular capillary lumens, the image was converted to 8-bit grayscale with the same freehand outline surrounding the glomerulus. Using the “threshold” tool set to “percentile” mode, a glomerulus was thresholded such that the capillary lumens were selected/isolated. Using the “measure” tool, the thresholded area was obtained in micrometers squared. The ratio [thresholded area (μm2)]/[total glomerular cross-sectional area (μm2)] gave the fraction of glomerular cross sections occupied by capillary lumens. For Jones’ silver–stained glomeruli, the “threshold” tool set to “percentile” mode was again used as follows: each glomerulus was thresholded so that darkly stained glomerular tissue was selected/isolated. Using the “measure” tool, the area occupied by silver-stained tissue was obtained in micrometers squared. The equation [stained area (μm2)]/[(glomerular cross-sectional area − capillary lumen area) (μm2)] gave the proportion of glomerular tissue that was stained.

Immunofluorescence staining

Isolation, embedding, and cryosectioning (5-μm sections) of renal cortex were described previously (Elimam ). WT1 immunofluorescent stain was described previously (Elimam ). For synaptopodin and podocalyxin immunostaining, kidney sections were air dried and fixed in 4% paraformaldehyde. Slides were washed in PBS and incubated in blocking solutions (containing BSA or nonimmune serum) for 1 h at 22°C in a humidified chamber. Slides were incubated with primary antibody or nonimmune control IgG overnight at 4°C, in a humidified chamber. Slides were washed with PBS and incubated with secondary antibody for 1 h at 22°C in a humidified chamber. In general, as a final step, stained slides were washed with PBS and incubated with 1 μg/ml Hoechst H33342 nuclear stain for 10 min at 37°C in a humidified chamber. For sheep anti-GBM and C3 immunofluorescence staining, cryosections were air dried and fixed in acetone at −20°C. Slides were blocked in 5% normal rabbit serum (sheep IgG) or 5% normal goat serum (C3) and 5% BSA in PBS for 15 min at 24°C. Slides were incubated with FITC-conjugated rabbit anti-sheep IgG or FITC-conjugated goat anti-mouse C3 for 2 h at 22°C. Sections were stained with Hoechst H33342 as described. Fluorescence imaging was performed on a Zeiss AXIO Observer.Z1 microscope. Images were collected with a Zeiss AxioCam MRm monochrome camera at an exposure length set to avoid saturation. For WT1 images, the number of fluorescent red nuclei that colocalized with Hoechst nuclear stain were counted (per glomerulus). For podocalyxin, synaptopodin, sheep anti-GBM antibody, and C3, glomeruli were encircled with a freehand region of interest (ImageJ). Cross-sectional area and fluorescence intensity were obtained within the freehand region of interest using the “measure” tool in ImageJ.

Electron microscopy and quantification of podocyte foot-process effacement

Kidney cortex was separated on ice, cut into 1.5 × 2 μm tissue blocks, and fixed in a solution of 2.5% glutaraldehyde in sodium cacodylate buffer (0.2 M C2H7AsO2, pH 7.4, with 0.1% CaCl and 0.2 M sucrose) at 4°C. Tissue preparation for electron microscopy and electron microscopic imaging was carried out at the McGill University Facility for Electron Microscopy Research as described previously (Elimam ). ImageJ software was calibrated according to the image magnification, and the number of podocyte foot processes was counted along a given length of GBM. Absolute foot process width (FPW) was calculated in micrometers as follows: FPW = π/4 × ∑GBM length/∑slits (Gundersen ; Elimam ).

Fluorescence quantification of autophagic puncta and FLAG immunostaining

Cells transfected with mCherry-eGFP-LC3B and FLAG-hIRE1α adherent to coverslips were washed with PBS at 22°C and fixed in ice-cold 4% paraformaldehyde in PBS for 15 min. Coverslips were washed three times with PBS at room temperature and incubated in 1 μg/ml Hoechst H33342 nuclear stain in PBS for 10 min at 37°C. Coverslips were then washed with PBS at 22°C and mounted on slides. Fluorescence imaging was conducted as described. Images were analyzed for puncta using ImageJ software as described previously (Elimam ), except that particles <0.1 μm2 and >100 μm2 were excluded. For immunofluorescence staining of the IRE1α FLAG epitope, coverslips were fixed, blocked, and incubated with monoclonal anti-FLAG primary antibody. Next coverslips were incubated with Alexa 546–conjugated donkey anti-mouse IgG in 3% BSA in PBS for 1 h at 37°C. Coverslips were then washed with PBS and incubated with 1 μg/ml Hoechst H33342 nuclear stain and mounted as described.

Statistics

Data are presented as mean ± SEM. Unless otherwise indicated, data were compared as arbitrary units (percentage of maximum value in the data set). All statistical tests were conducted with the program R (The R Foundation). One-tail t tests were used to assess differences between two groups. For more than two groups, analysis of variance (ANOVA) was used (Rao, 2007) as specified in the figure legends. For two-way ANOVAs conducted on data sets for which groups had unequal sample numbers, type 2 sum-of-squares ANOVA tests were conducted for data sets with no significant interaction terms. For data sets with a substantial interaction between factors, the type 1 ANOVA was conducted twice, with one factor leading the other and then vice versa. Once both ANOVA tests were completed, the test that gave the least significant p values for all comparisons was used. All post hoc comparisons and adjustments of the critical p value were conducted according to the Bonferroni method.
  56 in total

Review 1.  Protein misfolding and disease: the case of prion disorders.

Authors:  C Hetz; C Soto
Journal:  Cell Mol Life Sci       Date:  2003-01       Impact factor: 9.261

2.  Experimental glomerulonephritis.

Authors:  D J Salant; A V Cybulsky
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

3.  Methods in mammalian autophagy research.

Authors:  Noboru Mizushima; Tamotsu Yoshimori; Beth Levine
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

4.  Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice.

Authors:  Björn Hartleben; Markus Gödel; Catherine Meyer-Schwesinger; Shuya Liu; Theresa Ulrich; Sven Köbler; Thorsten Wiech; Florian Grahammer; Sebastian J Arnold; Maja T Lindenmeyer; Clemens D Cohen; Hermann Pavenstädt; Dontscho Kerjaschki; Noboru Mizushima; Andrey S Shaw; Gerd Walz; Tobias B Huber
Journal:  J Clin Invest       Date:  2010-04       Impact factor: 14.808

Review 5.  Counting glomeruli and podocytes: rationale and methodologies.

Authors:  Victor G Puelles; John F Bertram
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

6.  Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy.

Authors:  Atsuko Tagawa; Mako Yasuda; Shinji Kume; Kosuke Yamahara; Jun Nakazawa; Masami Chin-Kanasaki; Hisazumi Araki; Shin-Ichi Araki; Daisuke Koya; Katsuhiko Asanuma; Eun-Hee Kim; Masakazu Haneda; Nobuyuki Kajiwara; Kazuyuki Hayashi; Hiroshi Ohashi; Satoshi Ugi; Hiroshi Maegawa; Takashi Uzu
Journal:  Diabetes       Date:  2015-09-17       Impact factor: 9.461

7.  Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines.

Authors:  Károly Varga; Asta Jurkuvenaite; John Wakefield; Jeong S Hong; Jennifer S Guimbellot; Charles J Venglarik; Ashutosh Niraj; Marina Mazur; Eric J Sorscher; James F Collawn; Zsuzsa Bebök
Journal:  J Biol Chem       Date:  2004-04-01       Impact factor: 5.157

8.  Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability.

Authors:  Takao Iwawaki; Ryoko Akai; Shinya Yamanaka; Kenji Kohno
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-15       Impact factor: 11.205

Review 9.  Fine-tuning of the unfolded protein response: Assembling the IRE1alpha interactome.

Authors:  Claudio Hetz; Laurie H Glimcher
Journal:  Mol Cell       Date:  2009-09-11       Impact factor: 17.970

10.  C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.

Authors:  M M Ruseva; M Takahashi; T Fujita; M C Pickering
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

View more
  15 in total

1.  Ste20-like kinase, SLK, a novel mediator of podocyte integrity.

Authors:  Andrey V Cybulsky; Joan Papillon; Julie Guillemette; Natalya Belkina; Genaro Patino-Lopez; Elena Torban
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

2.  The kinase PERK and the transcription factor ATF4 play distinct and essential roles in autophagy resulting from tunicamycin-induced ER stress.

Authors:  Morten Luhr; Maria Lyngaas Torgersen; Paula Szalai; Adnan Hashim; Andreas Brech; Judith Staerk; Nikolai Engedal
Journal:  J Biol Chem       Date:  2019-03-29       Impact factor: 5.157

Review 3.  The Interplay between the RNA Decay and Translation Machinery in Eukaryotes.

Authors:  Adam M Heck; Jeffrey Wilusz
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

4.  Endoplasmic reticulum-associated degradation is required for nephrin maturation and kidney glomerular filtration function.

Authors:  Sei Yoshida; Xiaoqiong Wei; Gensheng Zhang; Christopher L O'Connor; Mauricio Torres; Zhangsen Zhou; Liangguang Lin; Rajasree Menon; Xiaoxi Xu; Wenyue Zheng; Yi Xiong; Edgar Otto; Chih-Hang Anthony Tang; Rui Hua; Rakesh Verma; Hiroyuki Mori; Yang Zhang; Chih-Chi Andrew Hu; Ming Liu; Puneet Garg; Jeffrey B Hodgin; Shengyi Sun; Markus Bitzer; Ling Qi
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 5.  Organelle Stress and Crosstalk in Kidney Disease.

Authors:  Sho Hasegawa; Reiko Inagi
Journal:  Kidney360       Date:  2020-08-07

Review 6.  Acute Kidney Injury and Progression of Diabetic Kidney Disease.

Authors:  Samuel Mon-Wei Yu; Joseph V Bonventre
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

Review 7.  Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases.

Authors:  Andrey V Cybulsky
Journal:  Nat Rev Nephrol       Date:  2017-10-03       Impact factor: 28.314

8.  Diabetic nephropathy in mice is aggravated by the absence of podocyte IRE1 and is correlated with reduced kidney ADH1 expression.

Authors:  Liping Xie; Kaifeng Guo; Sijia Lu; Ning Wang; Yanping Wang; Haibing Chen; Junli Liu; Weiping Jia
Journal:  Ann Transl Med       Date:  2021-04

9.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.

Authors:  Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong
Journal:  Autophagy       Date:  2021-02-08       Impact factor: 13.391

10.  Urinary ERdj3 and mesencephalic astrocyte-derived neutrophic factor identify endoplasmic reticulum stress in glomerular disease.

Authors:  Nihad Tousson-Abouelazm; Joan Papillon; Julie Guillemette; Andrey V Cybulsky
Journal:  Lab Invest       Date:  2020-03-18       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.